Vertex Pharmaceuticals is anchored by cystic fibrosis as launches lag, JOURNAVX and CASGEVY add little revenue, and growth is ...

What Happened? Shares of biotech company Vertex Pharmaceuticals (NASDAQ:VRTX) jumped 3.8% in the afternoon session after ...

Vertex Pharmaceuticals (VRTX) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to ...

In the past week, Wolfe Research upgraded Vertex Pharmaceuticals from “Peer Perform” to “Outperform,” citing growing ...

BofA lowered the firm’s price target on Vertex Pharmaceuticals (VRTX) to $522 from $545 and keeps a Buy rating on the shares after the company reported topline Phase 2 results for suzetrigine in ...

Insights from analysts' 12-month price targets are revealed, presenting an average target of $496.45, a high estimate of $564.00, and a low estimate of $414.00. Witnessing a positive shift, the ...

Hardman Johnston Global Advisors, an investment management company, released its “Hardman Johnston Global Equity Strategy” ...

Ratings for Vertex Pharmaceuticals (NASDAQ:VRTX) were provided by 13 analysts in the past three months, showcasing a mix of bullish and bearish perspectives. In the table below, you'll find a summary ...

Investors with a lot of money to spend have taken a bearish stance on Vertex Pharmaceuticals (NASDAQ:VRTX). And retail traders should know. We noticed this today when the positions showed up on ...

I'm updating my recent “Buy” thesis on Vertex Pharmaceuticals Incorporated — spoiler alert, I am as bullish, if not more so, than I was back in September, despite a recent sell-off. Vertex's CF ...

Vertex Pharmaceuticals dominates the cystic fibrosis treatment market and recently has expanded into other therapeutic areas. The biotech predicts full-year 2025 revenue of as much as $12 billion.

Now, it’s worth noting Stock Advisor’s total average return is 991 % — a market-crushing outperformance compared to 196% for ...